Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for CRISPR Therapeutics AG (CRSP : NSDQ)
 
 • Company Description   
CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

Number of Employees: 473

 
 • Price / Volume Information   
Yesterday's Closing Price: $56.34 Daily Weekly Monthly
20 Day Moving Average: 1,486,675 shares
Shares Outstanding: 77.46 (millions)
Market Capitalization: $4,363.93 (millions)
Beta: 2.05
52 Week High: $169.76
52 Week Low: $42.51
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.46% 14.26%
12 Week -1.43% 8.35%
Year To Date -25.65% -8.92%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
BAARERSTRASSE 14
-
ZUG,V8 CH-6300
CHE
ph: 41-41-561-3277
fax: -
susan.kim@crisprtx.com http://www.crisprtx.com
 
 • General Corporate Information   
Officers
Samarth Kulkarni - Chief Executive Officer
Rodger Novak - President
Brendan Smith - Chief Financial Officer
Ali Behbahani - Director
Bradley Bolzon - Director

Peer Information
CRISPR Therapeutics AG (CORR.)
CRISPR Therapeutics AG (RSPI)
CRISPR Therapeutics AG (CGXP)
CRISPR Therapeutics AG (BGEN)
CRISPR Therapeutics AG (GTBP)
CRISPR Therapeutics AG (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: H17182108
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 77.46
Most Recent Split Date: (:1)
Beta: 2.05
Market Capitalization: $4,363.93 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-2.23 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-8.97 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 12.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 15.61
PEG Ratio: -
Price Ratios
Price/Book: 1.94
Price/Cash Flow: 10.52
Price / Sales: 4.77
EPS Growth
vs. Year Ago Period: -53.64%
vs. Previous Quarter: -26.09%
Sales Growth
vs. Year Ago Period: 74.40%
vs. Previous Quarter: -92.71%
ROE
03/31/22 - 12.77
12/31/21 - 16.21
09/30/21 - 19.19
ROA
03/31/22 - 11.25
12/31/21 - 14.48
09/30/21 - 17.33
Current Ratio
03/31/22 - 19.88
12/31/21 - 20.17
09/30/21 - 26.18
Quick Ratio
03/31/22 - 19.88
12/31/21 - 20.17
09/30/21 - 26.18
Operating Margin
03/31/22 - 34.04
12/31/21 - 41.28
09/30/21 - 45.64
Net Margin
03/31/22 - 34.04
12/31/21 - 41.28
09/30/21 - 45.64
Pre-Tax Margin
03/31/22 - 34.58
12/31/21 - 41.48
09/30/21 - 46.08
Book Value
03/31/22 - 28.98
12/31/21 - 31.35
09/30/21 - 32.98
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©